Redeye updates its estimates and valuation following Vitec releasing its Q4 2022 report. The company’s sales growth exceeded our expectations, while margins were slightly lower than we estimated. We nudge up our sales growth estimates and elongate our forecast period by one year. We bump up our base case by c8%.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.